-
Eversana Forms Strategic Alliance with China Resource Pharmaceutical for Healthcare Expansion
•
US-based commercial services provider Eversana has announced a strategic alliance with China Resource Pharmaceutical Commercial Group. The collaboration aims to expand access to healthcare solutions, including both drugs and devices, with a focus on global products entering the Chinese market and domestic companies expanding into overseas markets. Enhancing Healthcare Innovation…
-
Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs
•
Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody drug conjugates (ADCs) within an existing deal with China’s Duality Biologics. This move follows Adcendo’s initial licensing agreement in January 2023, which granted access to Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker-payload platform for…
-
State Council Mandates Enhanced Oversight of Medical Insurance Funds Utilization
•
The State Council has issued the “Implementation Opinions on Strengthening the Normalization Supervision of the Use of Healthcare Security Funds,” outlining a comprehensive approach to enhance the oversight and management of healthcare security funds. The document clarifies the main responsibilities of various departments and sets forth regulatory measures to ensure…
-
NMPA Issues Procedures for Enhancing Children’s Medication Information in Drug Inserts
•
The National Medical Products Administration (NMPA) has released the “Procedures for Adding Children’s Medication Information to the Package Inserts of Marketed Drugs,” which are effective immediately. The new procedures aim to enhance the information on children’s medication in the instructions of marketed drugs, ensuring safe medication practices for children. Applicability…
-
Jiangsu Hengrui Medicine’s SHR-1905 and SHR7280 Receive NMPA Clinical Trial Approvals
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from the National Medical Products Administration (NMPA) for two of its drugs, SHR-1905 and SHR7280. SHR-1905 will be assessed for the treatment of chronic sinusitis with nasal polyps, while SHR7280 is intended for controlled superovulation in…
-
Brii Biosciences Initiates Phase I Study for BRII-297 in Australia
•
China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I clinical study assessing the safety, tolerability, and pharmacokinetics of its BRII-297 in healthy subjects in Australia. This marks a significant step in the development of the drug candidate, which is being closely watched for its…
-
AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron BA.5 mRNA vaccine, LVRNA012, based on a trial conducted on the China mainland. The study, which aimed to assess the protective efficacy, safety, and immunogenicity of LVRNA012 as a booster shot in individuals aged 18…
-
National Health Commission Unveils Action Plan for Medical Quality Improvement (2023-2025)
•
The National Health Commission (NHC) has released the “Action Plan for Comprehensive Improvement of Medical Quality (2023-2025)”, outlining a strategic approach to further establish quality and safety awareness within the medical industry. The plan aims to enhance the quality and safety management system and mechanism across the sector and to…
